Clinical Trial Update: GALLANT 4 Tesaglitazar vs. Glibenclamide [Phase 3]

View source ↗

Summary

A Phase 3 trial (GALLANT 4) comparing tesaglitazar to glibenclamide in Type 2 diabetes mellitus was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glibenclamide (glibenclamide)
• Tesaglitazar (tesaglitazar)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 3 | Status: TERMINATED